Chargement des cours...
Prévisions
Aucune donnée d'analyste n'est disponible pour cette entreprise.
Discussions dans la communauté
Il n'y a pas encore de discussion sur cet actif.
Lancer une discussionActualités Accéder au fil d'actualités
Novacyt launches IVDR-certified Yourgene Insight DPYD test in Europe
Novacyt has introduced the IVDR-certified Yourgene Insight DPYD test for the European market and can now commercially distribute it in regulated markets. The test detects 19 clinically relevant variants in the DPYD gene, including all current tier‑1 and tier‑2 variants, and according to the company is the first CE-marked DPYD test under the IVDR with this variant coverage. Novacyt developed the product with clinicians and previously offered the test in May 2026 as research-use-only. » Plus sur de.investing.com
Novacyt achieves 18% revenue growth in first half of 2026
Novacyt reports H1 2026 revenue of £11.6m, an increase of 18% year on year. The instruments segment grew around 30% thanks to the LightBench Discover platform, while the clinical business rose by more than 20% driven by demand for non‑invasive prenatal tests and products for treating sickle cell disease. The acquisition of Southern Cross Diagnostics contributed £1.8m post‑acquisition; sales increased by over 30% in the Americas and by about 22% in Asia-Pacific. Novacyt is implementing a restructuring programme expected to deliver up to £4.0m in annual cost savings and anticipates IVDR approval for the DPYD kit in the coming months. » Plus sur de.investing.com
Novacyt publishes annual report and financial statements for 2025
Novacyt has published its annual report and financial statements for the year ended 31 December 2025 and made them available on the company website. The company, which specializes in molecular diagnostics, reports on its three business divisions—clinical diagnostics, instrumentation and research use only—and highlights its global presence in more than 65 countries. Novacyt lists locations in Le Vésinet, Manchester, Singapore, the USA and Canada, and notes the acquisition of Southern Cross Diagnostics in Australia in March 2026. » Plus sur de.investing.com
Novacyt schedules general meeting for 30 June and announces investor presentation
Novacyt will hold its annual general meeting on 30 June 2026 at 11:00 CEST at the Hilton Paris Charles de Gaulle. CEO Lyn Rees and CFO Steve Gibson will deliver an investor presentation on the day of the meeting via the Investor Meet Company platform; the presentation will have automatic French captions. Investors can register for the webinar through the platform; the following users will automatically receive an invitation. » Plus sur de.investing.com
Novacyt: CSO Joanne Mason resigns with immediate effect
Novacyt said Dr. Joanne Mason is stepping down from her role as chief scientific officer and board member with immediate effect to pursue new professional opportunities. Mason served in the role for six years and helped shape the scientific direction and R&D foundations of the molecular diagnostics company. The company gave no information on a successor or further details. » Plus sur de.investing.com
Dividendes historiques Dividendes
Tous les indicateurs de dividendes Tous les indicateursDonnées financières de l'entreprise
| (EUR) | juin 2026 | YoY |
|---|---|---|
| Chiffre d'affaires | 13,27 M | 132,65 % |
| Bénéfice brut | 6,14 M | 22,44 % |
| Bénéfice net | -6,65 M | 78,95 % |
| EBITDA | -4,46 M | 73,39 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 37,7 M € |
Nombre d'actions | 72,47 M |
Plus haut/bas sur 52 semaines | 0,52 € - 0,44 € |
| Dividendes | Non |
Bêta | 1,11 |
Ratio P/E | -0,76 |
Ratio PEG | -0,04 |
Ratio P/B | 1,42 |
Ratio P/S | 0,81 |
Profil de l'entreprise
Novacyt S.A., ainsi que ses filiales, se consacre au développement, à la fabrication, à la conception sous contrat et à la commercialisation de produits de diagnostic pour le cancer et les maladies infectieuses au Royaume-Uni, dans le reste de l'Europe, aux États-Unis, dans la zone Asie-Pacifique, au Moyen-Orient et en Afrique. Le groupe opère à travers Primer Design, Lab21 Products et IT-IS International. Le segment Primer Design conçoit, fabrique et commercialise des dispositifs et réactifs de test qPCR en temps réel moléculaire dans le domaine des maladies infectieuses. Le segment Lab21 Products développe, fabrique et distribue une gamme de produits de diagnostic in vitro (DIV) à base de protéines pour les maladies infectieuses. Le segment IT-IS International développe et fabrique des appareils PCR destinés aux sciences de la vie et au secteur du contrôle alimentaire. Il dessert les hôpitaux et les entreprises. La société a été constituée en 2006 et son siège se trouve à Vélizy-Villacoublay, en France.
| Nom | Novacyt |
| PDG | Lyn Dafydd Rees |
| Siège social | Le Vésinet,
if France |
| Site web | |
| Introduction en bourse | 12/10/2012 |
| Employés | 234 |
Deep Dive
Symboles boursiers
| Bourse | Symbole |
|---|---|
Euronext | ALNOV.PA |
London Stock Exchange | NCYT.L |
Pnk | NVYTF |
Frankfurt | NYZ.F |
Düsseldorf | NYZ.DU |
London | NCYT.L |
Paris | ALNOV.PA |
München | NYZ.MU |